Adi Nagler

968 total citations · 1 hit paper
11 papers, 369 citations indexed

About

Adi Nagler is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Adi Nagler has authored 11 papers receiving a total of 369 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Immunology. Recurrent topics in Adi Nagler's work include Single-cell and spatial transcriptomics (2 papers), Signaling Pathways in Disease (2 papers) and Peptidase Inhibition and Analysis (2 papers). Adi Nagler is often cited by papers focused on Single-cell and spatial transcriptomics (2 papers), Signaling Pathways in Disease (2 papers) and Peptidase Inhibition and Analysis (2 papers). Adi Nagler collaborates with scholars based in Israel, United States and Netherlands. Adi Nagler's co-authors include Shelly Kalaora, Yardena Samuels, Jennifer A. Wargo, Israël Vlodavsky, Irving M. Ariel, A Hochberg, Mark Pines, N DEGROOT, Michael Elkin and Michal Alon and has published in prestigious journals such as Nature Communications, Nature reviews. Cancer and Blood.

In The Last Decade

Adi Nagler

10 papers receiving 365 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Mechanisms of immune activation and regulation: lessons from melanoma

2022 149 citations Shelly Kalaora, Adi Nagler et al. Nature reviews. Cancer profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Adi Nagler Israel	9	212	121	103	59	39	11	369
Roberta Mazzone Italy	9	281 1.3×	91 0.8×	80 0.8×	51 0.9×	23 0.6×	9	468
Daniel R. Matson United States	12	368 1.7×	84 0.7×	120 1.2×	44 0.7×	52 1.3×	31	604
Selvi Ramasamy United States	5	256 1.2×	156 1.3×	100 1.0×	48 0.8×	30 0.8×	8	377
Dionisia Quiroga United States	9	150 0.7×	188 1.6×	192 1.9×	83 1.4×	74 1.9×	33	500
Elke Malenke Germany	9	126 0.6×	92 0.8×	82 0.8×	22 0.4×	31 0.8×	13	303
Zhenqing Feng China	12	201 0.9×	77 0.6×	179 1.7×	48 0.8×	38 1.0×	30	408
Lesley A. Mathews Griner United States	11	273 1.3×	148 1.2×	158 1.5×	39 0.7×	29 0.7×	18	514
Eugene Froimchuk United States	9	329 1.6×	130 1.1×	67 0.7×	51 0.9×	40 1.0×	9	543
Aloke Sarkar United States	14	273 1.3×	100 0.8×	105 1.0×	69 1.2×	24 0.6×	20	492

Countries citing papers authored by Adi Nagler

Since Specialization

Citations

This map shows the geographic impact of Adi Nagler's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Adi Nagler with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Adi Nagler more than expected).

Fields of papers citing papers by Adi Nagler

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Adi Nagler. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Adi Nagler. The network helps show where Adi Nagler may publish in the future.

Co-authorship network of co-authors of Adi Nagler

This figure shows the co-authorship network connecting the top 25 collaborators of Adi Nagler. A scholar is included among the top collaborators of Adi Nagler based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Adi Nagler. Adi Nagler is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

1.

Penter, Livius, Adi Nagler, Nicoletta Cieri, et al.. (2024). Integrative genotyping of cancer and immune phenotypes by long-read sequencing. Nature Communications. 15(1). 32–32. 15 indexed citations

2.

Maurer, Katie, Adi Nagler, Jacob Shapiro, et al.. (2024). A Clonally Expanded Nodal T Cell Population Diagnosed As T Cell Lymphoma after CAR-T Therapy. Blood. 144(Supplement 1). 910–910.

3.

Nagler, Adi & Catherine J. Wu. (2022). The end of the beginning: application of single-cell sequencing to chronic lymphocytic leukemia. Blood. 141(4). 369–379. 4 indexed citations

4.

Kalaora, Shelly, Adi Nagler, Jennifer A. Wargo, & Yardena Samuels. (2022). Mechanisms of immune activation and regulation: lessons from melanoma. Nature reviews. Cancer. 22(4). 195–207. 149 indexed citations breakdown →

5.

Nagler, Adi, Shelly Kalaora, Chaya Barbolin, et al.. (2021). Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics. Cell Reports. 35(13). 109305–109305. 35 indexed citations

6.

Nagler, Adi, David W. Vredevoogd, Michal Alon, et al.. (2019). A genome‐wide CRISPR screen identifies FBXO42 involvement in resistance toward MEK inhibition in NRAS‐mutant melanoma. Pigment Cell & Melanoma Research. 33(2). 334–344. 19 indexed citations

7.

Alon, Michal, Rand Arafeh, Sanna Madan, et al.. (2018). CAPN1 is a novel binding partner and regulator of the tumor suppressor NF1 in melanoma. Oncotarget. 9(58). 31264–31277. 11 indexed citations

8.

Prabhu, Ponnandy, et al.. (2015). Inhibition of APOBEC3G activity impedes double‐stranded DNA repair. FEBS Journal. 283(1). 112–129. 9 indexed citations

9.

Zcharia, Eyal, Ruth Atzmon, Adi Nagler, et al.. (2012). Inhibition of matrix metalloproteinase-2 by halofuginone is mediated by the Egr1 transcription factor. Anti-Cancer Drugs. 23(10). 1022–1031. 19 indexed citations

10.

Elkin, Michael, Irving M. Ariel, Adi Nagler, et al.. (1999). Inhibition of bladder carcinoma angiogenesis, stromal support, and tumor growth by halofuginone.. PubMed. 59(16). 4111–8. 79 indexed citations

11.

Kapelushnik, Joseph, Reuven Or, Dvora Filon, et al.. (1995). Analysis of beta-globin mutations shows stable mixed chimerism in patients with thalassemia after bone marrow transplantation. Blood. 86(8). 3241–3246. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact